Advertisement

Surgery Today

, Volume 27, Issue 10, pp 883–891 | Cite as

Advances in the development of immunosuppressive agents in organ transplantation

  • Takenori Ochiai
  • Kaichi Isono
Editorials
  • 58 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cecka JM, Terasaki PI (1992) The UNOS scientific renal transplant registry. In: Terasaki PI, Cecka JM (eds) Clinical transplants. UCLA Tissue Typing Laboratory, Los Angeles, pp. 1–16Google Scholar
  2. 2.
    Gjertson DW, Takemoto S, Cecka JM, Terasaki PI (1995) Impact of allocating cadaveric kidneys solely to “Centers of Excellence” versus by HLA matching. Transplant Proc 27:653–655PubMedGoogle Scholar
  3. 3.
    Iwasaki Y, Amemiya H, Uchiyama G, Hanaoka T, Odaka M, Kamiya K (1974) Post-operative care and clinical results. In: Iwasaki Y (ed) Cadaveric renal transplantation. Igakushoin, Tokyo, pp 79–99Google Scholar
  4. 4.
    Amlot Pl, Rawlings E, Fernando ON, Griffin PJ, Heinrich G, Schreier MH, Castange JP, Moore R, Sweny P (1995) Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 60:748–756PubMedGoogle Scholar
  5. 5.
    Murray JE (1991) The first successful organ transplants in man. In: Terasaki PI (ed) History of Transplantation. UCLA Tissue Typing Laboratory, Los Angeles, pp 123–143Google Scholar
  6. 6.
    Merrill JP, Murray JE, Harrison JH (1956) Successful homotransplantation of the human kidney between identical twins. JAMA 160:277–282Google Scholar
  7. 7.
    Calne RY (1961) Inhibition of the rejection of renal homografts in dogs by purine analogues. Transplant Bull 26:65–81Google Scholar
  8. 8.
    Zukoski CF, Lee HM, Hume DM (1960) The prolongation of functional survival of canine renal homografts by 6-MP. Surg Forum 11:470–472PubMedGoogle Scholar
  9. 9.
    Calne R (1991) Recollections from the laboratory to the clinic. In: Terasaki PI (ed) History of transplantation. UCLA Tissue Typing Laboratory, Los Angeles, pp 229–243Google Scholar
  10. 10.
    Calne RY, Murray JE (1961) Inhibition of the rejection of renal homografts in dogs by Burroughs Wellcome 57-222. Surg Forum 12:118PubMedGoogle Scholar
  11. 11.
    Murray JE, Merrill JP, Harrison JH (1963) Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med 268:1315–1323PubMedGoogle Scholar
  12. 12.
    Merrill JP, Murray JE, Takacs F (1963) Successful transplantation of kidney from a human cadaver. JAMA 185:347–353PubMedGoogle Scholar
  13. 13.
    Goodwin WE, Kaufman JJ, Mims MM (1963) Human renal transplantation. J Urol 89:13–24PubMedGoogle Scholar
  14. 14.
    Starzl TE, Marchioro TL, Waddel WR (1963) The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg Gynecol Obstet 117: 385–395PubMedGoogle Scholar
  15. 15.
    Murray JE, Barnes BA, Atkinson JC (1967) Fifth report of the human kidney transplant registry. Transplantation 5:752–774PubMedGoogle Scholar
  16. 16.
    Starzl TE, Marchioro TL, Von Kaulla KN, Hermann G, Brittain RS, Waddell WR (1963) Homotransplantation of the liver in humans. Surg Gynecol Obstet 117:659–676PubMedGoogle Scholar
  17. 17.
    Hardy JD, Webb WR, Dalton ML Jr, Walker GR (1963) Lung homotransplantation in man. JAMA 186:1065–1074PubMedGoogle Scholar
  18. 18.
    Lillehei RC, Idezuki Y, Feemster JA, Dietzman RH, Kelly WD, Merkel FK, Goetz FC, Lyons GW, Manax WG (1967) Transplantation of stomach, intestine and pancreas. Surgery 62:721–741PubMedGoogle Scholar
  19. 19.
    Barnard CN (1968) What we have learned about heart transplants. J Thorac Cardiovasc Surg 56:457–468PubMedGoogle Scholar
  20. 20.
    Iwasaki Y, Takahashi H, Odaka M, Uematsu S, Ohkawa H, Amemiya H, Yokoyama K, Sato H (1969) Clinical application of orthotopic hepatic allografting (in Japanese). Geka 31:1381–1389Google Scholar
  21. 21.
    Ogoshi S, Okamura T (1974) Selection of cadaveric donor. In: Iwasaki Y (ed) Cadaveric renal transplantation. Igakushoin, Tokyo, pp 4–13Google Scholar
  22. 22.
    Belzer FO (1994) Kidney. In: History of the American Society of Transplant Surgeons. Stanton, Minneapolis, pp 235–248Google Scholar
  23. 23.
    Starzl TE, Koep L, Porter KA, Schroter GPJ, Weil III R, Hartley RB, Halgrimson CG (1980) Decline in survival after liver transplantation. Arch Surg 115:815–819PubMedGoogle Scholar
  24. 24.
    Iwasaki Y, Porter KA, Amend JR, Marchioro TL, Zuhlke V, Starzl TE (1967) The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. Surg Gynecol Obstet 124:1–24PubMedGoogle Scholar
  25. 25.
    Starzl TE, Porter KA (1968) Antilymphocyte globulins. In: Rappaport FT, Dausset J (eds) Human transplantation. Grune & Stratton, New York, pp 489–498Google Scholar
  26. 26.
    Cosimi AB, Wortis HH, Delmonico FL, Russel PS (1976) Randomized clinical trial of antilymphocyte globulin in cadaver renal allograft recipients. Surgery 80:155–163PubMedGoogle Scholar
  27. 27.
    Ochiai T, Asano T, Sato H, Kashiwagi N, Fukao K, Amemiya H, Ohtsubo O, Taguchi Y, Kashiwabara H (1982) Results of multiinstitutional controlled study of ALG (in Japanese). Ishoku 17:391–400Google Scholar
  28. 28.
    Ochiai T, Ahmed A, Strong DM, Scher I, Sell KW (1975) Specificity and immuno-suppressive potency of a rabbit anti-mouse T cell specific antiserum. Transplantation 20:198–210PubMedGoogle Scholar
  29. 29.
    Cosimi AB, Burton RC, Colvin RB (1981) Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32:535–539PubMedGoogle Scholar
  30. 30.
    Cecka M, Cicciarelli J (1985) The transfusion effect. In: Terasaki P (ed) Clinical kidney transplant. UCLA Tissue Typing Laboratory, Los Angeles, pp 73–92Google Scholar
  31. 31.
    Ochiai T, Gunji Y, Nagata M, Isono K (1983) Cyclosporine enhances an effect of donor-specific blood transfusion in canine renal transplantation. Transplant Proc 156:2939–2941Google Scholar
  32. 32.
    Borel JF (1982) The history of Cyclosporine A and its significance. In: White DJG (ed) Cyclosporine A. Elsevier, Amsterdam, pp 5–17Google Scholar
  33. 33.
    Borel JF, Baumann G, Chapman I (1996) In vivo pharmacological effects of cyclosporine and some analogues. Adv Pharmacol 35:115–246PubMedGoogle Scholar
  34. 34.
    Calne RY, White DJG, Rolles K (1978) Prolonged survival of pig or orthotopic heart grafts treated with cyclosporine. Lancet 1:1183–1185PubMedGoogle Scholar
  35. 35.
    Calne RY, White DJG, Thiru S (1978) Cyclosporine A in patients receiving renal allografts from cadaver donors. Lancet 2:1323–1327PubMedGoogle Scholar
  36. 36.
    Starzl TE, Iwatsuki S, Shaw BW, Gordon RD (1986) Liver transplantation in the Cyclosporine era. Prog Allergy 38:366–394PubMedGoogle Scholar
  37. 37.
    Ochiai T, Toma H, Takagi H, Oka T, Ishibashi M, Kashiwabara H, Ota K, Hashimoto I, Sonoda T, Iwasaki Y (1987) Japanese multicenter trial of Cyclosporine in renal transplantation. Transplant Proc 19:2961–2966PubMedGoogle Scholar
  38. 38.
    Kino T, Hatanaka H, Miyata S, Inamura N, Yajima T, Goto T, Okuhara M, Kosaka M, Aoki H, Ochiai T (1987) FK-506, a novel immunosuppressant isolated from a Streptomyces. J Antibiot 40:1256–1265PubMedGoogle Scholar
  39. 39.
    Ochiai T, Nagata M, Nakajima K, Suzuki T, Sakamoto K, Nakagohri T, Asano T, Isono K, Hamaguchi K, Goto T (1987) Studies on the effects of FK506 on renal allografting in the beagle dog. Transplantation 44:723–733Google Scholar
  40. 40.
    Ochiai T, Nakajima K, Nagata M, Hori S, Asano T, Isono K (1987) Studies on the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation of rats. Transplantation 44:734–738PubMedGoogle Scholar
  41. 41.
    Todo S, Podesta L, ChapChap P (1987) Orthotopic liver transplantation in dogs receiving FK506. Transplant Proc 19 Suppl 6:64–67PubMedGoogle Scholar
  42. 42.
    Lim SML, Thiru S, White DJG (1987) Heterotopic heart transplantation in the rat receiving FK506. Transplant Proc 19 Suppl 6:68–70PubMedGoogle Scholar
  43. 43.
    Todo S, Ueda Y, Demetris JA (1988) Immunosuppression of canine, monkey, and baboon allografts by FK506. Surgery 104:239–249PubMedGoogle Scholar
  44. 44.
    Starzl TE, Todo S, Fung J (1989) FK506 for liver, kidney and pancreas transplantation. Lancet 2:1000–1004PubMedGoogle Scholar
  45. 45.
    Inamoto T, Nishizawa F, Sasaki H, Tanaka K, Yamaoka Y (1996) Experience of 120 microsurgical reconstructions of hepatic artery in living related liver transplantation. Surgery 119:20–26Google Scholar
  46. 46.
    Ochiai T, Ishibashi M, Fukao K, Takahashi K, Endo T, Yokoyama I, Uchida K, Ohshima S, Takahara S, Morozumi K, Yamaguchi Y, Kyo M, Sonoda T, Takagi H, Oka K, Iwasaki Y (1995) Japanese multicenter studies of FK506 in renal transplantation. Transplant Proc 27:50–53PubMedGoogle Scholar
  47. 47.
    Sehgal SN, Baker H, Vezina C (1975) Rapamycin, a new antifungal antibiotic. J Antibiot 28:721–726PubMedGoogle Scholar
  48. 48.
    Martel RR, Klicius J, Galet S (1977) Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 55:48–51PubMedGoogle Scholar
  49. 49.
    Hollander GA, Bierer BE, Burakoff SJ (1996) Molecular mechanisms of immunosuppressive drugs: Cyclosporine A, FK506 and Rapamycin. In: Tilney NL, Strom TB, Paul LC (eds) Transplantation biology. Lippincott-Raven, Philadelphia, pp 657–671Google Scholar
  50. 50.
    Calne RY, Collier D St J, Lims (1989) Rapamycin for immunosuppression in organ allografting. Lancet 2:227PubMedGoogle Scholar
  51. 51.
    Ochiai T, Gunji Y, Nagata M, Isono K (1993) Effects of Rapamycin in experimental organ transplantation. Transplantation 56:15–19PubMedGoogle Scholar
  52. 52.
    Morris RE (1992) Rapamycins: antifungal, antitumor, antiproliferative and immunosuppressive macrolides. Transplant Rev 6:39–87Google Scholar
  53. 53.
    Fruman DA, Burakoff SJ, Bierer BF (1994) Molecular actions of Cyclosporine A, FK506 and Rapamycin. In: Thomson AW, Starzl TE (eds) Immunosuppressive drugs. Edward Arnold, London, pp 15–35Google Scholar
  54. 54.
    Schreiber SL (1991) Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251:283–287PubMedGoogle Scholar
  55. 55.
    Schreiber SL, Crabtree GR (1992) The mechanisms of action of Cyclosporine A and FK506. Immunol Today 13:136–142CrossRefPubMedGoogle Scholar
  56. 56.
    Rao R (1994) NF-A Tp: A transcription factor required for the coordinate induction of several cytokine genes. Immunol Today 15:274–281CrossRefPubMedGoogle Scholar
  57. 57.
    Taniguchi M, Minami Y (1993) The IL-2/IL-2 receptor system. Cell 73:5–8CrossRefPubMedGoogle Scholar
  58. 58.
    Fruman DA, Burakoff SJ, Bierer BE (1994) Immunophilins in protein folding and immunosuppression. FASEB J 8:391–400PubMedGoogle Scholar
  59. 59.
    Sigal NH, Dumont F, Durette P, Siekerka JJ, Peterson L, Rich DH (1991) Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of Cyclosporine A? J Exp Med 172:619–628Google Scholar
  60. 60.
    Chiu MI, Katz H, Berlin V (1994) A mammalian homologue of yeast TOR interacts directly with the FKBP 12/rapamycin complex. Proc Natl Acad Sci USA 91:12574–12578PubMedGoogle Scholar
  61. 61.
    Todo S, Fung JJ, Starzl TE (1994) Single-center experience with primary orthotopic liver transplantation with FK506 immunosuppression. Ann Surg 220:297–309PubMedGoogle Scholar
  62. 62.
    The US multicenter FK506 liver study group (1994) A comparison of Tacrolimus and Cyclosporine for immunosuppression in liver transplantation. N Engl J Med 331:1110–1115Google Scholar
  63. 63.
    Williams R, Neuhaus P, Bismuth H (1996) Two-year data from the European multicenter Tacrolimus liver study. Transpl Int 9 Suppl 1:s144-s150PubMedGoogle Scholar
  64. 64.
    Woodle ES, Thistlethwaite JR, Gordon JH, Laskow D, Deierhoi MH, Burdick J (1996) A multicenter trial of FK506 therapy in refractory acute renal allograft rejection. Transplantation 62:594–599PubMedGoogle Scholar
  65. 65.
    van Hoff J, The European Tacrolimus Multicenter Renal Study Group (1996) The European multicenter prospective randomized trial comparing Tacrolimus and Cyclosporine in the prevention of renal allograft rejection. 16th International Congress of the Transplantation Society, BarcelonaGoogle Scholar
  66. 66.
    Inomata Y, Tanaka K, Egawa H, Uemoto S, Ozaki N, Okajima H, Satomura K, Kiuchi T, Yamaoka Y, Hashida T (1996) The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. Transplantation 61:247–252PubMedGoogle Scholar
  67. 67.
    Uemoto S, Tanaka K, Honda K, Tokunaga Y, Sano K, Katoh H, Yamamoto E, Takada Y, Ozawa K (1993) Experience with FK506 in living-related liver transplantation. Transplantation 55:288–292PubMedGoogle Scholar
  68. 68.
    Kahan BD, Pescovitz M, Julian B, Chan G, Vanrenterghem Y (1996) Multi-center Phase II trial of Sirolimus in renal transplantation. XVI International Congress of the Transplantation Society, BarcelonaGoogle Scholar
  69. 69.
    Gjertson M, Cecka JM, Terasaki PI (1995) The relative effects of FK506 and Cyclosporine on short and long term kidney graft survival. Transplantation 60:1384–1388PubMedGoogle Scholar
  70. 70.
    Wang T, Donahue PK, Zervos AS (1994) Specific interaction of type I receptors of the TGF β family with the immunophilin FKBP12. Science 265:674–676PubMedGoogle Scholar
  71. 71.
    Ahuja S, Shrivastav S, Daielpour D, Balow J (1995) Regulation of transforming growth factor-β and its receptor by cyclosporine in human T-lymphocytes. Transplantation 60:718–723PubMedGoogle Scholar
  72. 72.
    Jutila MA (1994) Role of changes in the vascular endothelium in chronic inflammation. Clin Transpl 8:304–307Google Scholar
  73. 73.
    Lemster BH, Carroll PB, Rilo HR (1995) IL8/IL8 receptor expression in psoriasis and the response to systemic Tacrolimus therapy. Clin Exp Immunol 99:148–154PubMedGoogle Scholar
  74. 74.
    Manez R, Jain A, Marino IR, Thomson AW (1995) Comparative evaluation of Tacrolimus (FK506) and Cyclosporine A as immunosuppressive agents. Transplant Rev 9(2):63–76CrossRefGoogle Scholar
  75. 75.
    Faulds D, Goa KI, Benfield P (1993) Cyclosporine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 45:953PubMedGoogle Scholar
  76. 76.
    Fung JJ, Alessiani M, Abu-Elmagd K, Todo S, Shapiro R, Tzakis A, Starzl TE (1991) Adverse effects associated with the use of FK506. Transplant Proc 23:3105–3108PubMedGoogle Scholar
  77. 77.
    Ochiai T, Sakamoto K, Gunji Y, Isono K (1989) Effects of combination treatment with FK506 and Cyclosporine on survival time and vascular changes is renalallograft recipient dogs. Transplantation 48:193–197PubMedGoogle Scholar
  78. 78.
    Mueller EA, Kovarik JM, van Bree JB, Lison AE (1994) Safety and steady-state pharmacokinetics of a new oral formulation of Cyclosporine A in renal transplant patients. Transplant Int 7 Suppl 1:s267-s269Google Scholar
  79. 79.
    Polland SG, Lodge PJ, UK Neoral Renal Study Group (1996) Neoral vs Sandimmune: interim results of a randomized trial of efficacy and safety in preventing actue rejection in new renal transplant recipients. 16th International Congress of the Transplantation Society, BarcelonaGoogle Scholar
  80. 80.
    Ochiai T, Gunji Y, Nagata M, Isono K (1991) Effective and safe use of FK506: combination treatment with Rapamycin and RS-61443 in experimental organ transplantation. Transplant Proc 23:2718–2719PubMedGoogle Scholar
  81. 81.
    Kirkman RL, Barrett LV, Gaulton GN, Kelley VE, Ythier A, Strom TB (1985) Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med 162:358–362CrossRefPubMedGoogle Scholar
  82. 82.
    Neuhaus P, Bechstein WO, Blumhardt G, Wiens M, Lemmens P, Langehr JM, Lohmann R, Steffen R, Schlag H, Slama KJ, Lobeck H (1993) Comparison of quadruple immunosuppression after liver transplantation with ATG or IL-2 receptor antibody. Transplantation 55:1320–1327PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • Takenori Ochiai
    • 1
  • Kaichi Isono
    • 1
  1. 1.Department of SurgeryChiba University School of MedicineChibaJapan

Personalised recommendations